What is NDC 27241-125?

27241-125 is the product NDC for Ranolazine, Ranolazine 500 mg/1 tablet, extended release, listed with the FDA by Ajanta Pharma USA Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.

Ajanta Pharma USA Inc., NDC labeler code 27241. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Ranolazine?

51 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Ranolazine NDC 27241-125 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)27241-125Labeler and product segments. Claims need a package NDC.

Product NDC at billing width27241-0125Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
27241-125-02	2724101250227241012502	60 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-125-02)Marketed from Aug 23, 2019
27241-125-05	2724101250527241012505	500 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-125-05)Marketed from Jul 14, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ranolazine
Generic name (nonproprietary): ranolazine
Active ingredients: Ranolazine — 500 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Ajanta Pharma USA Inc.NDC labeler code 27241
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210054
Marketing start: Aug 23, 2019
Listing expires: Dec 31, 2026
Other FDA classes: Cytochrome P450 2D6 Inhibitors (Mechanism)Cytochrome P450 3A Inhibitors (Mechanism)Organic Cation Transporter 2 Inhibitors (Mechanism)P-Glycoprotein Inhibitors (Mechanism)
Identifiers: Product ID 27241-125_933f695e-e4f4-4c75-80fc-aea9a30aa13dSPL ID 933f695e-e4f4-4c75-80fc-aea9a30aa13dSPL set ID 8bfd1a61-547a-4847-ae4e-480b17da6272RxCUI 616749, 728231UNII A6IEZ5M406UPC 0327241125027, 0327241126024
Pharmacologic class: Anti-anginal

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N427241012502 followed by a unit qualifier and the quantity

Package 27241-0125-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 28, 2025.

Indications (excerpt from the label)

Ranolazine extended-release tablets are indicated for the treatment of chronic angina. Ranolazine extended-release tablets may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. Ranolazine is an antianginal indicated for the treatment of chronic angina. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 27241-125

What is NDC 27241-125?: 27241-125 is the product NDC for Ranolazine, Ranolazine 500 mg/1 tablet, extended release, listed with the FDA by Ajanta Pharma USA Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Ranolazine.
What is the active ingredient?: Ranolazine.
Who is the labeler?: Ajanta Pharma USA Inc., NDC labeler code 27241. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Ranolazine?: 51 other product NDCs are listed under this name. See all Ranolazine NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Ranolazine NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Ranolazine	Ranolazine 500 mg/1	Tablet, Extended releaseOral	Umedica Laboratories USA Inc.	60290-055	60290-0055-0160290-0055-03
Ranolazine	Ranolazine 1000 mg/1	Tablet, Extended releaseOral	Umedica Laboratories USA Inc.	60290-056	60290-0056-0160290-0056-03
Ranolazine	Ranolazine 500 mg/1	Tablet, Film coated, Extended releaseOral	Torrent Pharma, Inc.	13668-759	13668-0759-60
Ranolazine	Ranolazine 1000 mg/1	Tablet, Film coated, Extended releaseOral	Torrent Pharma, Inc.	13668-760	13668-0760-60
Ranolazine	Ranolazine 500 mg/1	Tablet, Film coated, Extended releaseOral	Zameer Pharmaceuticals LLC	90096-151	90096-0151-60
Ranolazine	Ranolazine 1000 mg/1	Tablet, Film coated, Extended releaseOral	Zameer Pharmaceuticals LLC	90096-152	90096-0152-60
Ranolazine	Ranolazine 500 mg/1	Tablet, Film coated, Extended releaseOral	Radha Pharmaceuticals, Inc	77771-423	77771-0423-60
Ranolazine	Ranolazine 1000 mg/1	Tablet, Film coated, Extended releaseOral	Radha Pharmaceuticals, Inc	77771-424	77771-0424-60
Ranolazine	Ranolazine 500 mg/1	Tablet, Film coated, Extended releaseOral	Aphena Pharma Solutions - Tennessee, LLC	71610-971	71610-0971-42
Ranolazine	Ranolazine 500 mg/1	Tablet, Film coated, Extended releaseOral	A2A Integrated Pharmaceuticals	73141-021	73141-0021-02

All 52 Ranolazine NDCs

Other NDCs under ANDA 210054

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210054
Product	Strength	Form · route	Labeler	Product NDC
Ranolazine	Ranolazine 1000 mg/1	Tablet, Extended releaseOral	Ajanta Pharma USA Inc.	27241-126
Ranolazine	Ranolazine 500 mg/1	Tablet, Extended releaseOral	American Health Packaging	60687-549